Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares dropped 4.7% on Tuesday . The company traded as low as $3.38 and last traded at $3.41, with a volume of 171,508 shares trading hands. The stock had previously closed at $3.58.

DRNA has been the subject of a number of research reports. Chardan Capital initiated coverage on shares of Dicerna Pharmaceuticals in a research report on Monday, April 4th. They set a “neutral” rating and a $5.00 target price for the company. Stifel Nicolaus reduced their target price on shares of Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Jefferies Group reissued a “buy” rating and set a $19.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $11.95.

The firm’s market capitalization is $68.60 million. The company has a 50-day moving average of $3.41 and a 200-day moving average of $5.04.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.10. On average, analysts predict that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.